Skip to main content
SpringerLink
Log in

Activity of Doxorubicin Covalently Bound to a Novel Human Serum Albumin Microcapsule

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Doxorubicin is widely used in the treatment of human malignancies, however is associated with significant cardiac, bone marrow and gastro-intestinal toxicity. Delivery systems may ameliorate this toxicity and increase treatment specificity by increasing the proportion of drug delivered to sites of disease. We have developed a novel preparation of doxorubicin (Dox) covalently linked to a heat stabilised human serum albumin microparticle (HSAM) carrier (median particle diameter of 4 μm) and assessed its activity in 4 malignant cell lines.

Materials and methods. Doxorubicin microcapsules were compared with free doxorubicin in the rat carcinoma cell line, WRC256, and the human lines, OVCAR3, MCF7 and the Dox resistant MCF7/Dox, using a cell counting technique. IC50 were calculated from regression analysis of the resulting survival curves. Endocytosis of the microcapsules by cells in culture was observed. The rate of microcapsule uptake was assessed using dual wavelength filtered fluorescence microscopy and flow cytometry.

Results. The mean IC50 following incubation with the Dox microcapsules was around 5 times greater than Dox for WRC256 (p < 0.001), MCF7 (p < 0.01) and for OVCAR3 (p < 0.01). MCF7/Dox was significantly more sensitive to Dox microcapsules than free Dox (p = 0.034). A negative correlation between the rate of microcapsule uptake and the IC50 values for each cell line in culture exists (r = −0.96, p = 0.04).

Conclusions. We conclude that: 1) Doxorubicin microcapsules retain activity in vitro and appear to overcome p-glycoprotein mediated Dox resistance. 2) The observed activity of Dox microcapsules correlates with the rate of particle uptake. Further studies in animal tumour models are in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Legha SS, Benjamin RS, Mackay B, Yap HY, Wallace S, Ewer M, Blummenschein GR, Freireich EJ: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96: 133–137, 1982

    Google Scholar 

  2. Gupta PK, Gallo JM, Hung CT, Perrier DG: Influence of the stabilisation temperature on the entrapment of adriamycin in albumin microspheres. Drug Develop Indust Pharm 13: 1471–1482, 1987

    Google Scholar 

  3. Gupta PK, Hung CT: Albumin microspheres I: Physicochemical characteristics. J Microencapsulation 6: 426–462,1989

    Google Scholar 

  4. Tomlinson E, Burger JJ, Schoonderwoerd EMA, McVie JG: Human serum albumin microspheres for intra-arterial drug targeting of cytostatic compounds. Pharmaceutical aspects and release characteristics. In: Davis SS, Illum L, McVie JG, Tomlinson E (eds) Microspheres and Drug Therapy. Pharmaceutical, Immunological and Medical Aspects. Elsevier, New York, 1984, pp 75–90

    Google Scholar 

  5. Visscher GE, Pearson JE, Fong JW, Argentieri GJ, Robison RL, Maulding HV: Effect of particle-size on the in vitro and in vivo degradation rates of poly(dl-lactide-co-glycolide) microcapsules. J Biomed Materials Res 22: 733–746, 1988

    Google Scholar 

  6. Goldberg JA, Thomson JAK, Bradnam MS, Fenner J, Bessent RG, Mckillop JH, Kerr DJ, Mcardle CS: Angiotensin-II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases. Br J Cancer 64:114–119, 1991

    Google Scholar 

  7. Goldberg JA, Willmott K, Kerr DJ, Sutherland C, McArdle CS: An in vivo assessment of adriamycin loaded albumin microspheres. Br J Cancer 65: 393–395, 1992

    Google Scholar 

  8. Cummings, J, Willmott N, Marley E, Smyth JF: Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition. Biochem Pharmacol 41: 1849, 1991

    Google Scholar 

  9. Willmott N, Cummings J: Increased anti-tumour effect of adriamycin-loaded albumin microspheres is associated with anaerobic bioreduction of drug in tumour tissue. Biochem Pharmacol 36: 521, 1987

    Google Scholar 

  10. Astier A, Doat B, Ferrer MJ, Benoit G, Fleury J, Rolland A, Leverge R: Enhancement of adriamycin antitumor-activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in u-937 cells. Cancer Res 48:1835–1841, 1988

    Google Scholar 

  11. Tollemar J, Andersson S, Ringden O, Tyden G: A retrospective clinical comparison between antifungal treatment with liposomal amphoteracin B (Ambisome) and conventional amphoteracinn B in transplant recipients. Mycoses 35: 215–220,1992

    Google Scholar 

  12. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnettn A, Greco FA, Morrow P, Paradiso LJ, Liand LJ: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Anti-tumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987–993, 1997

    Google Scholar 

  13. Gill PS, Espina BRN, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM: Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13: 996–1003, 1995

    Google Scholar 

  14. Forssen EA, Coulter DM, Proffitt RT: Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52: 3255–3261, 1992

    Google Scholar 

  15. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46: 6387–6392, 1986

    Google Scholar 

  16. Trouet A, Masquelier M, Baurain R, Deprez DE, Campeneere D: A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as 120 required for a lysosomotropic drug-carrier conjugate - in vitro and in vivo studies. Proc Nat Ac Sci USA 79: 626–629, 1982

    Google Scholar 

  17. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterisation of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379–5389, 1983

    Google Scholar 

  18. Benchekroun MN, Schneider E, Safa AR, Townsend AJ, Sinha BK: Mechanism of resistance of ansamycin antibiotics in human breast cancer cell lines. Mol Pharmacol 46: 677–684,1994

    Google Scholar 

  19. Zyad A, Benard J, Tursz T, Clarke R, Chouaib S: Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res 54: 825–831, 1994

    Google Scholar 

  20. Mechetner E, Kyshoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP: Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlates with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389–398, 1998

    Google Scholar 

  21. Ferry DR, Traunecker H, Kerr DJ: Clinical trials of Pglycoprotein reversal in solid tumours. Eur J Cancer 32A: 1070–1081, 1996

    Google Scholar 

  22. Tritton TR, Yee G: The anticancer agent adriamycin can be actively cyto-toxic without entering cells. Science 217: 248-250, 1982

    Google Scholar 

  23. Wingard LJ, Tritton JR, Egler KA: Cell surface effects of adriamycin and carcinomycin immobilized on cross-linked polyvinyl alcohol. Cancer Res 45: 3529–2536, 1985

    Google Scholar 

  24. HenryToulme N, Grouselle M, Ramaseilles C: Multidrug resistance bypass in cells exposed to doxorubicin-loaded nanospheres. Absence of endocytosis. Biochem Pharmacol 50:1135–1139, 1995

    Google Scholar 

  25. Suzuki S, Watanabe S, Uno S, Tanaka M, Masuko T, Hashimoto T: Endocytosis does not necessarily augment the cytotoxicity of adriamycin encapsulated in immunoliposomes. Biochimica et Biophysica Acta - Molecular Cell Research 1224: 445–453, 1994

    Google Scholar 

  26. De Verdiere AC, Dubernet C, Nemati F, Soma E, Appel M, Ferte J, Bernard S, Puisieux F, Couvreur P: Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action. Br J Cancer 76: 198–205,1997

    Google Scholar 

  27. Robertson KW, Reeves J, Stanton PD, Cooke TG, Ozanne B: Breast cancer cell invasion is modulated by the EGF receptor (Abstract). Br J Cancer 14(Suppl 28): 21, 1996

    Google Scholar 

  28. Nemati F, Dubernet C, de Verdiere AC, Poupon MF, Treupelacar L, Puisieux F, Couvreur P: Some parameters influencing cytotoxicity of free doxorubicin and doxorubicin-loaded nanoparticles in sensitive and multidrug-resistant leukemic murine cells - incubation-time, number of nanoparticles per cell. Int J Pharm 102: 55–62, 1994

    Google Scholar 

  29. Suzuki S, Uno S, Fukuda Y, Aoki Y, Masuko T, Hashimoto Y: Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br J Cancer 72: 663–668,1995

    Google Scholar 

  30. Duncan R, Cable HC, Lloyd JH: Degradation of side chains of N-(2-hydroxypropyl)methacrylamide) copolymers by lysosomal thiolproteinases. Bioscience Rep 2: 1041–1046, 1982

    Google Scholar 

  31. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC, Deeley RG: Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 55: 102–110, 1995

    Google Scholar 

  32. de Jong S, Zijlistra JG, de Vries EG, Mulder NH: Reduced DNA topoisomerase II activity and drug induced DNA cleavage activity in an adriamycin resistant human small cell lung carcinoma cell line. Cancer Res 50: 304–309, 1990

    Google Scholar 

  33. Anderson JH, Angerson WJ, Willmott N, Kerr DJ, McArdle CS, Cooke TG: Regional delivery of microspheres to liver metastases: the effects of particle size and concentration on intrahepatic distribution. Br J Cancer 64: 1031–1034, 1991

    Google Scholar 

  34. Kato T, Sato K, Sasaki R, Kakinuma H, Moriyama M: Targeted cancer-chemotherapy with arterial microcapsule chemoembolization - review of 1013 patients. Cancer hemother Pharmacol 37: 289–296, 1996

    Google Scholar 

  35. Jain RK: Transport of macromolecules in tumor microcirculation.Biotechnol Prog 1: 81–94, 1985

    Google Scholar 

  36. Jain RK: Transport of molecules across tumour vasculature.Cancer Met Rev 6: 559–593, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Glasgow Royal Infirmary NHS Trust, Glasgow, UK

    Martin Eatock

  2. Andaris Limited, Ruddington, Nottingham, UK

    Nicola Church & Roy Harris

  3. University Department of Surgery, Glasgow Royal Infirmary NHS Trust, Glasgow, UK

    Wilson Angerson & Colin McArdle

  4. CRC Department of Medical Oncology, University of Glasgow, Bearsden, UK

    Ray French & Chris Twelves

Authors
  1. Martin Eatock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Church
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roy Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wilson Angerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Colin McArdle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ray French
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chris Twelves
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eatock, M., Church, N., Harris, R. et al. Activity of Doxorubicin Covalently Bound to a Novel Human Serum Albumin Microcapsule. Invest New Drugs 17, 111–120 (1999). https://doi.org/10.1023/A:1006362915317

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006362915317

Search

Navigation